NEW YORK (GenomeWeb) – Foundation Medicine said today that it is entering a strategic collaboration with Novartis focused on developing companion diagnostic tests for the company's portfolio of targeted oncology and immuno-oncology drugs.

According to Foundation, the collaboration structure includes development, regulatory support and commercialization of CDx tests using its US Food and Drug Administration-approved comprehensive genomic profiling assay, FoundationOne CDx.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.